BackgroundTwo studies were conducted assessing the efficacy of NexGard® PLUS (NP) in preventing heartworm disease. Study 1 evaluated the efficacy of six monthly doses of NP or Simparica Trio® (ST) against a macrocyclic lactone-resistant isolate of heartworm, Dirofilaria immitis, and study 2 evaluated the efficacy of a single dose of NP against a susceptible isolate.MethodsIn two studies, dogs that were negative for heartworms by antigen test and modified Knott’s test were used. In study 1, dogs were randomly allocated into three treatment groups (n = 6/group): negative control, NP per label instructions, and ST per label instructions. Dogs were inoculated with 50 third-stage D. immitis larvae (JYD-34 isolate) on day −30. NP and ST were administered orally on days 0, 30, 60, 90, 120, and 150. A necropsy was performed on day 180 for adult heartworm recovery. In study 2, dogs were randomly allocated into two treatment groups (n = 10/group): negative control and NP. Dogs were inoculated with 50 third-stage larvae (SC-20 isolate) on day −30. NP was administered orally once on day 0 to target the minimum moxidectin label dose. A necropsy was performed on day 120 for adult heartworm recovery.ResultsFor study 1, all control dogs had adult heartworms at necropsy (geometric mean, 39.7; range, 28–48). Two of the NP-treated dogs had one live worm, and one of the ST-treated dogs had one live worm. Both treated groups were significantly different from the control group with an efficacy of 99.5% for NP and 99.8% for ST (P < 0.0001). There was no significant difference (P = 0.8797) between the groups treated with NP and ST. For study 2, all control dogs had adult heartworms (geometric mean, 34.5; range 26–43). None of the dogs treated with NP had live adult worms (efficacy of 100%, P < 0.0001).ConclusionsThe results of study 1 demonstrated that NexGard® PLUS and Simparica Trio® administered at the label dose provided comparable efficacy against a macrocyclic lactone-resistant isolate of D. immitis. The results of study 2 demonstrated that NexGard® PLUS administered once near the minimum label dose was 100% effective against a susceptible isolate.Graphical
Read full abstract